A brief history
Anecdotal evidence of cancer remission following viral infection.
Development of cell culture, description of oncolysis, clinical trials but pathogenic viruses.
Development of engineered attenuated/non-pathogenic virus to treat cancer:
- Attenuated Herpes virus mutant (Martuza et al. Science. 1991).
Virotherapy in the clinic
2015-FDA approval of T-vec: an attenuated Herpes virus expressing GMCSF.
First virotherapy approved for CNS tumors
THE MAIN ASPECTS THAT CONTRIBUTE TO A POOR PROGNOSIS IN PEOPLE WITH CNS TUMORS:
Blood-brain barrier physiologic isolation precluding drug delivery;
Resistance of cancer stem cells to conventional therapy;
The immune-privileged isolation of the CNS (cold tumors).